These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3589697)

  • 1. Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias.
    Capizzi RL; Powell BL
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):40-50. PubMed ID: 3589697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
    Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
    J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
    Capizzi RL; Poole M; Cooper MR; Richards F; Stuart JJ; Jackson DV; White DR; Spurr CL; Hopkins JO; Muss HB
    Blood; 1984 Mar; 63(3):694-700. PubMed ID: 6696996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.
    Morra E; Lazzarino M; Brusamolino E; Pagnucco G; Castagnola C; Bernasconi P; Orlandi E; Corso A; Santagostino A; Bernasconi C
    Cancer; 1993 Jul; 72(2):439-45. PubMed ID: 8319175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
    Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia.
    Capizzi RL; Cheng YC
    Med Pediatr Oncol; 1982; 10 Suppl 1():221-8. PubMed ID: 6962320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
    Grümayer ER; Schmidmeier W; Panzer S; Gadner H
    Blut; 1986 Oct; 53(4):309-14. PubMed ID: 3756357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose Ara-C treatment of acute leukemia].
    Takaku F
    Gan To Kagaku Ryoho; 1986 May; 13(5):1823-8. PubMed ID: 3707145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
    Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM-CSF and asparaginase potentiate ara-C cytotoxicity in HL-60 cells.
    Powell BL; Wang LM; Gregory BW; Case LD; Kucera GL
    Leukemia; 1995 Mar; 9(3):405-9. PubMed ID: 7885038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.